OS Fund is a venture capital firm that focuses on early-stage, computationally driven science and technology companies. Their strategy involves investing in breakthrough discoveries in fields such as genomics, synthetic biology, computationally derived therapeutics, advanced materials, and diagnostics, with the goal of addressing global challenges and "rewriting the operating systems of life."
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (50% of deals). Average disclosed round size is $26.6M (across 5 rounds with reported amounts).
Portfolio
6
Fund Size
$695.3M
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Arzeda | Series B | $33M | Mar 2022 |
 Verge Genomics | Series A | $32M | Jul 2018 |
 3Scan Inc. | Series B | $14M | Jul 2016 |
 Ginkgo Bioworks | Series B | $45M | Jul 2015 |
| Ginkgo Bioworks | Series A | $9M | Mar 2015 |
 Synthego | Unknown | — | — |
Top Co-Investors
Y Combinator2 shared
Felicis Ventures2 shared
Data Collective2 shared
DFJ Growth1 shared
Agent Capital1 shared
Draper Associates1 shared
Lifeforce Capital1 shared
Viking Global1 shared
Canvas Ventures1 shared
Lux Capital1 shared
Dolby Family Ventures1 shared
Comet Labs1 shared
Breakout Ventures1 shared
Founders Fund1 shared
8VC1 shared
Menlo Ventures1 shared
Lewis & Clark AgriFood1 shared
Casdin Capital1 shared
Last updated: 8 March 2026